ChromaDex
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1999-01-01
- Employees
- 106
- Market Cap
- $265M
- Website
- http://www.chromadex.com
- Introduction
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults
- Conditions
- MoodCognitive FunctionSleep
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- ChromaDex, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03562468
- Locations
- 🇺🇸
MB Clinical Research, Boca Raton, Florida, United States